Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Immediate Approval Of Pearson Health Claims Sought By Legislators

This article was originally published in The Tan Sheet

Executive Summary

FDA should "immediately" approve the four health claims that were the subject of the Pearson v. Shalala case, House Republicans Ron Paul (Tex.), Helen Chenoweth (Idaho), Merrill Cook (Utah), John Hostetler (Ind.) and Bob Stump (Ariz.) and Democrat Peter DeFazio (Ore.) state in a July 22 letter to the agency. FDA should "make all necessary changes to its rules, regulations and procedures to ensure compliance with the Pearson decision," they say.

You may also be interested in...



FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs

A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.

FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs

A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.

FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs

A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel